This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
Illumina (ILMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 30.16% and 0.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Illumina (ILMN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.
10 Stocks Leading the Rally in the S&P 500 ETF
by Sweta Killa
Signs of a slowdown in the number of hospitalizations and intensive-care admissions in New York and Europe has led to optimism over the reopening of the economy soon and improving activity in the near future.
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Stock Moves -1.75%: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session.
The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan
Top Research Reports for Apple, Facebook & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Apple (AAPL), Facebook (FB) and AbbVie (ABBV).
Illumina (ILMN) Stock Moves -1.9%: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $273, moving -1.9% from the previous trading session.
Why Is Illumina (ILMN) Down 12.2% Since Last Earnings Report?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD
by Kevin Cook
Do you know which investment whales were buying and selling your favorite stocks before the big rally to new highs?
Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
by Zacks Equity Research
Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.
Coronavirus: How Fast to 100,000 Infected?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Illumina (ILMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 6.92% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Coronavirus: Epidemic or Pandemic?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.